Prevalence of HIV-associated lipodystrophy in Brazilian outpatients: Relation with metabolic syndrome and cardiovascular risk factors;Prevalência da lipodistrofia associada ao HIV em pacientes ambulatoriais Brasileiros: Relação com síndrome metabólica e fatores de risco cardiovascular

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 4, 2008, Pages 658-667

  Diehl, Leandro A ^a   Dias, Janaína R ^a   Paes, Aline C S ^a   Thomazini, Maria C ^a   Garcia, Lorena R ^a   Cinagawa, Eduardo ^a   Wiechmann, Susana L ^a   Carrilho, Alexandre J F ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Brazil; HIV infections; HIV associated lipodystrophy syndrome; Metabolic syndrome X; Prevalence

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BODY MASS; BRAZIL; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; MALE; METABOLIC SYNDROME X; OUTPATIENT; PREVALENCE; RISK FACTOR; SEX DIFFERENCE;

ADULT; ANTI-HIV AGENTS; BODY MASS INDEX; BRAZIL; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; METABOLIC SYNDROME X; OUTPATIENTS; PREVALENCE; RISK FACTORS; SEX FACTORS;

EID: 47249141356     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302008000400012     Document Type: Article

References (36)

1. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-9.
2. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected patients. N Engl J Med. 2005;351:48-62.
3. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS. 2003;17 Suppl 1:S141-8.
4. Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS. 2005; 19 Suppl 4:S14-21.
5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.
6. Estrada V, Martínez-Larrad MT, González-Sánchez JL, Villar NGP, Zabena C, Fernández C, et al. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metab Clin Exp 2006;55:940-5.
7. Jericó C, Knobel H, Montero M, Ordoñez-Llanos J, Guelar A, et al. Metabolic syndrome among HIV-infected patients. Diabetes Care. 2005;28:144-9.
8. Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr. 2007;45:426-31.
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
10. Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1059-62.
11. Brasil. Ministério da Saúde. Estimativa de prevalência do HIV na população brasileira de 15 a 49 anos, 2004 [acesso em 2007 Apr 24]. Disponível em: http://www.aids.gov.br/data/ Pages/LUMIS72418C70PTBRIE.htm.
12. Chen D, Misra A, Garg A. Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab. 2002;87:4845-56.
13. Instituto Brasileiro de Geografia e Estatística (IBGE). Estimativa da população - 2004 [acesso em 2007 Apr 24]. Disponível em: http://www.ibge.gov.br/home/estatistica/população/estimativa2004/ estimativa.shtm.
14. Friis-Møller N, Weber R, Reiss P, Thiébault R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular risk factors in HIV patients: association with antiretroviral therapy. AIDS. 2003;17:1179-93.
15. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
16. Leow MKS, Addy CL, Mantzoros CS. Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab. 2003;88:1961-76.
17. Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-8.
18. Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr. 2005;39:199-202.
19. Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr. 2003;33:571-76.
20. Valente AMM, Reis AF, Machado DM, Succi RCM, Chacra AR. Alterações metabólicas da síndrome lipodistrófica do HIV. Arq Bras Endocrinol Metab 2005;49:871-81.
21. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-89.
22. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-82.
23. Asztalos BF, Schaefer EJ, Horvath KV, Cox CE, Skinner S, Gerrior J, et al. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis. 2005;184:72-7.
24. Nolan D, Mallal S. Getting to the HAART of insulin resistance. AIDS. 2001;15:2037-41.
25. Brar I, Shuter J, Thomas A, Daniels E, Absalon J. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort. J Acquir Immune Defic Syndr. 2007;45:66-71.
26. Ministério da Saúde. 1988. Estudo multicêntrico sobre a prevalência do diabete melito no Brasil [acesso em 2007 June 23]. Disponível em: http://tabnet.datasus.gov.br/cgi/idb2006/d10.htm.
27. Guimarães MMM, Greco DB, Ribeiro-Oliveira A Jr, Penido MG, Machado LJC. Distribuição da gordura corporal e perfis lipídico e glicêmico de pacientes infectados pelo HIV. Arq Bras Endocrinol Metab 2007;51:42-51.
28. Oliveira EP, Souza MLA, Lima MDA. Prevalência de síndrome metabólica em uma área rural do semi-árido baiano. Arq Bras Endocrinol Metab 2006;50:456-65.
29. Bruno R, Gazzaruso C, Sacchi P, Zocchetti C, Giordanetti S, Garzaniti A, et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J Acquir Immune Defic Syndr. 2002;31:363-5.
30. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III Criteria - associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care. 2007;30:113-9.
31. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis. 2007;44:726-34.
32. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death - a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-14.
33. van Wijk JPH, de Koning EJ, Cabezas MC, Joven J, op't Roodt J, Rabelink TJ, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol. 2006;47:1117-23.
34. Bonfanti P, Ricci E, Socio G, Zeme D, Carradori S, Penco G, et al. Metabolic syndrome: a real threat for HIV-positive patients? Results from the SIMONE Study. J Acquir Immune Defic Syndr. 2006;42:128-30.
35. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002;16:F1-8.
36. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:20251-4.